Two Stocks You May Need To Reconsider: CytRx Corporation

New Post Public Reply Private Reply Replies (1) Message Board
fitzkarz
400
Two Stocks You May Need To Reconsider: CytRx Corporation (CYTR), BioCryst Pharmaceuticals, Inc. (BCRX)
June 19, 2017

CytRx Corporation (NASDAQ:CYTR) trades at $0.57 having a market capitalization of $87.9 million. CYTR stock price lost -75.64% over the past year, yielding a negative weighted alpha of -35.99 percent. A weighted alpha below 0 suggest additional declines. Therefore, there is certainly still some pain for investors who want to avoid this falling stock.

Weighted Alpha is used to calculate how much a share has gone up or down over a certain period, normally a year. In general, more thrust is placed on most recent actions by assigning higher weights to it than those assigned to past movements. This assists to give a return figure that has a stronger focus on the most current period and is thus a better measure for short-term analysis. This technique is highly famous among technical analysts. If the stock is up it will have a positively weighted alpha. If the stock price is unchanged its weighted alpha will be smaller. A stock price loss will yield a negatively weighted alpha.
CytRx Corporation (NASDAQ:CYTR) Technical Metrics

Support is likely to come between $0.56 a share to $0.56 a share level. However, if the CYTR shares go below $0.56 then it would indicate a much weaker market for the company. In that case, its shares would mark a 1.75% decline from the most recent price. The typical day in the last two weeks has seen about a 7.79% volatility. The average volume for CytRx Corporation (NASDAQ:CYTR) has been 7.48 million shares per day over the past 30 days. CYTR has a 1-week performance of 1.48%. CYTR price is down nearly -368.42% from its 52-week high price of $2.67 a share but is up about 36.84% from its 52-week low price of $0.36 a share.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has accumulated 1.48% over the course of one week. It seems that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) might see strength given an ABR of 2 or Buy rating. Analysts, on average, seem bullish as they suggest BCRX is worth $3.08 more, giving a target price of $8.63 a share. CYTR share have rallied by 54.49% in percentage terms since the start of the year – and added 26.85% in the last month. Volume in the last session has increased compared with CYTR’s average trading volume. We think the increased volume is representative of buyers as it has displayed in many other cases.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Major Trends On The Chart

BCRX’s Stochastic Oscillator (%D) is at 65.76%. Values of %D line that are above 80 indicate that the security is overbought; prices could well fall in the near future. And the values below 20 that it is oversold indicate prices could very well bounce upwards. The Stochastic Oscillator is a powerful technical tool that is somewhat surprisingly easy to understand. In a basic sense, it is used by technicians to measure the “speed or momentum” of the price movement. It represents the location of the previous close relative to the price range over a set number of periods. This can be more easily understood, however, by pulling apart the two lines on the stochastic oscillator and explaining the simple underlying mathematical formulas. The first line is called the “%K” line, which analyzes the actual price movements in the shares and can be defined as: %K = (Current Close – Lowest Low)/(Highest High – Lowest Low) * 100. The second line, the “%D” line is simple a 3-day moving average of the “%K” line. There are three primary ways to read the Stochastic Oscillator in search of entry points, but traders should follow the %D line closely because that indicates major trends on the chart.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Critical Levels

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s latest quote $5.55 $-0.01 0.36% will find technical support in $5.43 a share and a breakdown below this region would be a significantly bearish signal for BioCryst Pharmaceuticals, Inc. traders. Any way you dice it, a dip below $5.31 a share would be very bad news for BCRX’s technical picture in the near-term. The $5.31 level represents at least another 4.32% downside for the stock from its current price. If BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares can stay above the price resistance around $5.66 a share, that could help propel BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) higher to the next line of resistance at $5.77 a share. The typical day in the last one month has seen about a 8.27% volatility. BCRX is down around 53.15% from its 12-month high of $2.6 notched on Jun 24, 2016 but is -66.67% above its highest point the past 12 months of $9.25 a shar
I'm in it to win it!

NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.

I was born with it, I'm truly blessed!


Alway's searching for winners'
937206596_images.jpg
Scroll down for more posts ▼

Top 10 Most Recent News Articles

GAC Revamps its Charge into Europe's EV Market

Updated Category News Views 2

A New Chapter in GAC's European Journey GAC isn’t tiptoeing into Europe; the Chinese automaker hit the ground running with the launch of its AION UT and AION V in Italy. This isn't just another car release. Oh no, it’s GAC's grand entrance into a market saturated with well-established players. On October 8th, amidst the artistic vibes of Milan’s Superstudio Più,...

Continue Reading
Carrier Drops $600M on U.S. Manufacturing Boost

Updated Category News Views 3

A Mighty Move in Manufacturing Carrier Global Corporation's recent muscle-flexing is something rarer than a golden goose in today's market—a $600 million thrust into beefing up U.S. manufacturing and engineering. You can't help but wonder if this is overzealous optimism or a meticulously calculated power play. Clocks don't tick this loudly without good reason, of...

Continue Reading
Berney Flowers Rings the Bell on Fiscal Reform

Updated Category News Views 5

Berney Flowers: A Voice for Fiscal Change Oh boy, Berney Flowers sure isn't holding back. The Maryland congressional candidate is out here on Biz Talk Today TV, aiming straight at the heart of government waste and promising fiscal reform with the kind of intensity you don't see every day. Through the airwaves, he's been championing independent audits to keep those...

Continue Reading
St. Croix Financial Hub: Game Changer or Fluff?

Updated Category News Views 10

You know, sometimes it feels like the financial world gets more tangled than a fishing line on a windy beach. This latest spiel coming out of St. Croix with all its big names and lofty promises—Governor Bryan’s 3rd Wall Street Financial District Hub Initiative—seems like one of those, but maybe it’s got more meat than hype. Half the pitch sounds like your typical...

Continue Reading
Veterinary Industry Could Unlock Growth by Empowering Technicians

Updated Category News Views 4

Doors Not Fully Open for Vet Technicians Here's the skinny: the vet industry’s sitting on a goldmine of untapped potential right under its nose. According to a fresh study by Penn Foster, there's a glaring disconnect between what vet techs are trained to handle and what they're actually allowed to do in practice. If practices start trusting these pros to do their thing,...

Continue Reading
Indegene Gains Accolades for AI-Driven Pharma Success

Updated Category News Views 2

Indegene's AI Revolution in Pharma There's a new player making noise on the pharma playground, and it's called Indegene. This company just snagged the 2026 Global Enabling Technology Leadership Recognition from Frost & Sullivan for shaking up pharmaceutical commercialization with its cutting-edge AI arsenal. No fluff here—just a straight dive into how they're turning...

Continue Reading
Dr. Anke Otto-Wolf's BEFORE Framework Revolutionizes SEL

Updated Category News Views 3

Teaching Kids to Catch Themselves: Introducing BEFORE Calling October Bullying Prevention Month seems quaint when you consider how often kids get shoved around, physically or emotionally. What’s surprising is how one simple word, ‘BEFORE,’ might just be the game-changer. Dr. Anke Otto-Wolf is betting big on it by unveiling the BEFORE Framework™. Imagine kids...

Continue Reading
Country Stars Illuminate Art in Philly, Mississippi

Updated Category News Views 2

A Mural Tribute to Country Music Roots Forget about skyscrapers and bustling metropolises; sometimes, it's about bringing a bit of soul back to the heartland. That's precisely what the unveiling of the "Wildflowers and Wild Horses" mural in Philadelphia, Mississippi, did. Lainey Wilson and Marty Stuart's Vision Partners in crime — or, more fittingly, in country —...

Continue Reading
Hard Rock Casino Tejon Commences $725M Expansion Project

Updated Category News Views 6

Ground Broken for Hard Rock Casino Tejon's Ambitious Expansion Who’s got a shovel ready? Hard Rock Casino Tejon does, kicking off a $725 million expansion that's turning heads all the way from Bakersfield to Los Angeles. Let's get something straight: this ain’t just another face-lift. We’re talking about a full-on transformation of the place into a plush resort...

Continue Reading
AI Tool circMAC Enhances MicroRNA Mapping on circRNAs

Updated Category News Views 3

Mapping the Complex Maze of MicroRNA on Circular RNAs Pusan National University's brainiacs have cooked up something spicy for the bioinformatics world. They've developed this snazzy AI tool, circMAC, to unravel microRNA binding mysteries on circular RNAs. 'Why’s this such a big deal?' you ask. Well, these loop-shaped critters, circRNAs, play a backstage role in gene...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Atlassian's Recent Options Activity Surge

Updated Category News Views 163

Analyzing Atlassian's Options Activity Recently, significant activity has been noted in the options market for Atlassian (NASDAQ: TEAM), suggesting fluctuating sentiment among investors. With several key trades occurring, it is vital to understand the underlying forces driving these changes. Insights from Options Trading An examination of options history indicates that a...

Continue Reading
Oncolytics Biotech's Strategic Move to Lead Cancer Innovation

Updated Category News Views 176

Oncolytics Biotech's Strategic Move to Lead Cancer Innovation In a time where the global oncology drug market is projected to exceed an astounding $900 billion, interest in cancer-focused biotechnology companies has surged significantly. Analysts highlight the increasing demand for innovative diagnostics and advanced immunotherapies driving this growth. Yet, as these...

Continue Reading
Transformations in Admirals Group AS Leadership and Governance

Updated Category News Views 170

Changes in Leadership at Admirals Group AS Admirals Group AS recently held a significant general meeting where key changes to its management and supervisory boards were decided. Effective from a stated future date, Anton Tikhomirov and Fedor Ragin have been appointed to the supervisory board for a term of five years. This shift marks an exciting new chapter in the...

Continue Reading
Athens Stock Market Reaches New Heights with Gains

Updated Category News Views 175

Athens Stock Market Performance Overview The latest updates reveal that Greece's stock market has closed on a positive note, showcasing notable increases across various sectors. The Athens General Composite Index has gained traction, finishing higher as key market sectors, particularly Construction, Travel, and Banking, experienced substantial growth. Sectorwise...

Continue Reading
Johnson & Johnson's Tremfya Shows Promising Results for Crohn's Disease

Updated Category News Views 227

Introduction to Tremfya and Crohn's Disease Tremfya, a medication developed by Johnson & Johnson, has gained notable attention for its role in treating Crohn's disease. Recently, new results from its Phase 3 GRAVITI study have sparked interest in its potential expanded usage, showing promising outcomes for patients. Exciting Results from the GRAVITI Study The GRAVITI...

Continue Reading